MediciBIO
Developer of RNA‑based therapeutic platforms focused on lipid‑based delivery and mutant‑selective oligonucleotide approaches. The organization describes platform capabilities for ionizable‑lipid mRNA lipid nanoparticle formulation, targeting‑lipid mediated tissue‑specific gene delivery, and RNA interference (RNAi) therapeutics intended to address genetic diseases.
Industries
biotechnology
clinical-trials
pharmaceutical
Nr. of Employees
small (1-50)
MediciBIO
Yongin, Ch'ungch'ong-namdo, South Korea, Asia
Products
Lipid nanoparticle delivery platform
Platform for formulation of mRNA and nucleic‑acid payloads using ionizable and targeting lipids to enable tissue‑directed delivery.
Mutant‑selective RNAi therapeutic candidates (pipeline)
Oligonucleotide‑based therapeutic candidates designed to selectively silence mutant alleles using RNAi approaches, presented as part of the company's development pipeline.
Lipid nanoparticle delivery platform
Platform for formulation of mRNA and nucleic‑acid payloads using ionizable and targeting lipids to enable tissue‑directed delivery.
Mutant‑selective RNAi therapeutic candidates (pipeline)
Oligonucleotide‑based therapeutic candidates designed to selectively silence mutant alleles using RNAi approaches, presented as part of the company's development pipeline.
Expertise Areas
- Lipid nanoparticle delivery
- Targeted gene delivery
- RNAi and oligonucleotide therapeutics
- mRNA formulation
Key Technologies
- Lipid nanoparticle (LNP) delivery
- Ionizable lipids
- Targeting lipids for tissue specificity
- RNA interference (RNAi)